Abstract
Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 642-652 |
| Number of pages | 11 |
| Journal | Journal of surgical oncology |
| Volume | 119 |
| Issue number | 5 |
| DOIs | |
| State | Published - Apr 1 2019 |
Keywords
- clinical trials
- colorectal cancer
- immunotherapy
- metastatic
- targeted therapy
ASJC Scopus subject areas
- Surgery
- Oncology